A unique mechanism of restenosis after drug-coated balloon in peripheral artery: Insight from optical frequency domain imaging

Cardiovasc Revasc Med. 2024 May:62:119-122. doi: 10.1016/j.carrev.2023.12.004. Epub 2023 Dec 11.

Abstract

Drug-coated balloons (DCBs) have been widely used in endovascular therapy for femoropopliteal arteries with atherosclerotic lesions. Vascular response after DCBs remains unclear. This mini-review proposes a possible mechanism of restenosis after the DCB strategy. Balloon dilatation including DCBs expands the vascular lumen by producing dissections, which is composed of the original vascular lumen and the cavity surrounded by dissected flaps. The cavity surrounded by dissected flaps is eventually replaced with the thrombus in the healing process after balloon dilatation. However, the thrombus may propagate to the expanded vascular lumen through the entry point of the dissection. Subsequently, the thrombus both in the cavity and the expanded lumen would be organized over time. The vascular lumen in the chronic-phase after DCBs may be influenced by the propagated thrombus from the cavity surrounded by dissected flaps.

Keywords: Drug-coated balloon; Optical frequency domain imaging; Peripheral artery; Restenosis.

Publication types

  • Review

MeSH terms

  • Angioplasty, Balloon* / adverse effects
  • Angioplasty, Balloon* / instrumentation
  • Cardiovascular Agents* / administration & dosage
  • Coated Materials, Biocompatible*
  • Constriction, Pathologic
  • Equipment Design
  • Femoral Artery / diagnostic imaging
  • Femoral Artery / physiopathology
  • Humans
  • Peripheral Arterial Disease* / diagnostic imaging
  • Peripheral Arterial Disease* / physiopathology
  • Peripheral Arterial Disease* / therapy
  • Popliteal Artery / diagnostic imaging
  • Popliteal Artery / physiopathology
  • Predictive Value of Tests
  • Recurrence*
  • Thrombosis / diagnostic imaging
  • Thrombosis / etiology
  • Thrombosis / physiopathology
  • Thrombosis / therapy
  • Tomography, Optical Coherence*
  • Treatment Outcome
  • Vascular Access Devices*

Substances

  • Coated Materials, Biocompatible
  • Cardiovascular Agents